Rheumatology – Medxy AI

History of Thrombosis and Hematologic Disease Double the Risk of New Clots in Persistently aPL‑Positive Patients: Prospective APS ACTION Registry Analysis

By MedXY 12/05/2025

In 1,067 persistently antiphospholipid antibody–positive patients followed for 4,727 person‑years, prior thrombosis and coexistent hematologic disease each conferred ~2‑fold increased risk for new thrombosis; microvascular disease and obesity showed trends.

Diabetes & Endocrinology news Rheumatology

Can an 11β‑HSD1 Inhibitor Improve Prednisolone’s Benefit–Risk Ratio in Polymyalgia Rheumatica? Early Human Trial Suggests Feasibility

By MedXY 12/05/2025

A single‑blind sequential cohort trial found that clofutriben, a selective 11β‑HSD1 inhibitor, reduced biomarkers of glucocorticoid toxicity while partially attenuating prednisolone efficacy at low doses; efficacy was restored at higher prednisolone doses, supporting further randomized trials.

news Rheumatology

EULAR 2025 Classification Criteria for Haemochromatosis Arthropathy: What Clinicians and Researchers Need to Know

By MedXY 12/04/2025

EULAR’s first-ever, evidence-based classification criteria for haemochromatosis arthropathy (HA) provide an 8-item, 11-point score (≥5 yields 93.3% specificity, 71.4% sensitivity) to standardize research cohorts of C282Y homozygous patients with iron loading and joint disease.

news Rheumatology

EAPSDAS: The First EULAR Disease Activity Score for Antiphospholipid Syndrome — What Clinicians Need to Know

By MedXY 12/04/2025

EULAR’s new antiphospholipid syndrome disease activity score (EAPSDAS) provides the first standardized, validated tool to measure APS activity across thrombotic, microvascular and obstetric manifestations — a major advance for clinical care and trials.

Clinical Updates news Rheumatology

Long-Term Impact of Treat-to-Target Urate-Lowering Therapy on Ultrasound-Detected Crystal Depositions and Clinical Outcomes: Insights from the 5-Year NOR-Gout Study

By MedXY 12/04/2025

The 5-year NOR-Gout study demonstrates that sustained low serum urate via treat-to-target therapy leads to dissolution of crystal deposits, reduced flares, and increased remission rates, highlighting the clinical value of long-term urate control in gout management.

news Rheumatology

Rapid, Durable Benefit of Upadacitinib Across Oligo‑ and Polyarticular Psoriatic Arthritis: Primary Findings from the Real‑World UPJOINT Study

By MedXY 12/04/2025

In the multicenter UPJOINT observational study, upadacitinib produced rapid and sustained improvements in minimal disease activity in both oligo- and polyarticular psoriatic arthritis over 48 weeks, with a safety profile consistent with prior trials.

news Rheumatology

UPsA Ultrasound Scores Bring Quantitative Activity and Damage Assessment to Psoriatic Arthritis — Feasible, Responsive Tools from a Multicentre Italian Study

By MedXY 12/04/2025

The UPsA activity and damage ultrasound scores (and a simplified sUPsA) were developed and internally validated in 312 PsA patients; they correlate moderately with clinical measures, are responsive to change (SRM overall 0.63; 1.03 in MDA achievers), and may improve objective monitoring of PsA.

news Rheumatology

Sustained Treat‑to‑Target Urate‑Lowering Therapy Clears Crystal Deposits and Cuts Flares: 5‑Year NOR‑Gout Follow‑Up

By MedXY 12/03/2025

Five‑year follow‑up of the NOR‑Gout treat‑to‑target urate‑lowering therapy program shows durable serum urate control, marked reduction and frequent dissolution of ultrasound‑detected MSU deposits, and a low residual flare rate linked to higher urate and residual crystal burden.

news Orthopedics Rheumatology

Ten-Year TOPKAT Follow-up: Partial (Unicompartmental) Knee Replacement Matches Total Replacement Clinically and Is More Cost-Effective

By MedXY 12/01/2025

The 10-year TOPKAT randomized trial found no clinically important difference in Oxford Knee Score between partial (PKR) and total knee replacement (TKR) for medial compartment osteoarthritis, similar revision/reoperation rates, and cost-effectiveness in favour of PKR.

news Rheumatology

Early IL‑17A Blockade vs Step‑Up Therapy in Psoriatic Arthritis: STAMP trial shows no superior 6‑month benefit for secukinumab-first treat‑to‑target strategy

By MedXY 12/01/2025

The STAMP randomized trial found that a treat‑to‑target strategy starting with secukinumab plus methotrexate did not achieve superior 6‑month ACR50 rates versus a conventional methotrexate‑first step‑up approach; 12‑month outcomes were similar for both strategies.

Dermatology news Rheumatology

Predicting Rare but Serious Harm: A Validated 100‑Day Risk Model for Allopurinol‑Induced Severe Cutaneous Adverse Reactions

By MedXY 12/01/2025

A large UK cohort study developed and externally validated a 100‑day prognostic model for allopurinol‑induced severe cutaneous adverse reactions (SCAR). Key predictors include age, CKD stage, high initial dose, and Asian ethnicity; discrimination was good (C≈0.8).

AI news Rheumatology

Deep learning classifies focus score and Sjögren’s disease from minor salivary gland biopsies and highlights a CD8+ acinar pattern

By MedXY 12/01/2025

A multicentre deep‑learning model reliably classified biopsy focus score and ACR‑EULAR–defined Sjögren’s disease (AUROC ≈0.88–0.89) and identified a novel CD8+ T‑cell peri‑acinar pattern associated with disease; prospective validation is needed.

Cardiology news Rheumatology

High Cardiovascular Risk but Poor Risk-factor Control in Antiphospholipid Syndrome — Worse in Primary APS than SLE-related APS

By MedXY 11/30/2025

A multinational cross-sectional study of 1003 people with antiphospholipid syndrome (APS) found high prevalence of hypertension, hyperlipidaemia, obesity and smoking, with suboptimal attainment of guideline targets — particularly among those with primary APS.

news Rheumatology

FcRn blockade with nipocalimab reduces disease activity in moderate‑to‑severe Sjögren’s syndrome: positive phase 2 DAHLIAS results

By MedXY 11/27/2025

In DAHLIAS, intravenous nipocalimab 15 mg/kg every 2 weeks for 22 weeks significantly reduced ClinESSDAI scores versus placebo in anti‑Ro seropositive patients with moderate‑to‑severe Sjögren’s disease, with a safety profile similar to placebo.

Dermatology news Rheumatology

Dual IL‑17A/IL‑17F blockade with sonelokimab produces robust clinical responses in active psoriatic arthritis: phase 2 randomized trial

By MedXY 11/12/2025

A phase 2 randomized, placebo‑controlled trial found sonelokimab — a nanobody that inhibits IL‑17A and IL‑17F — produced significant improvements in joint and skin outcomes in active psoriatic arthritis versus placebo, with an acceptable short‑term safety profile.

$Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach$

Hematology-Oncology news Rheumatology

Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach

By MedXY 11/12/2025

In a phase 1 trial, co‑infused autologous CD19- and BCMA-targeting CAR‑T cells produced 80% LLDAS/DORIS remission at 12 weeks in 15 refractory SLE patients, with manageable toxicity and evidence of eradication of autoreactive B‑cell and plasma‑cell clones.

news Orthopedics Rheumatology

Intra-articular Hyaluronic Acid Injections: Long-Term Benefits in Early-Stage Knee Osteoarthritis and Older Women

By MedXY 11/04/2025

Systematic review of 71 RCTs reveals that intra-articular hyaluronic acid injections offer initial symptom worsening but significant long-term relief, especially in early-stage knee osteoarthritis and older women; molecular weight’s role requires further study.

news Rheumatology

GZMK+ CD8+ T Cells Drive Selective Acinar Cell Loss and Interferon Signaling in Sjögren’s Disease

By MedXY 11/04/2025

Single-cell and spatial multi-omics reveal loss of a PRR4⁺CST3⁺ seromucous acinar population and accumulation of GZMK⁺CD8⁺ T cells that induce IFN-driven epithelial dysfunction in Sjögren’s disease.

Neurology news Rheumatology

Outcomes of Maintenance Immunotherapy in Susac Syndrome

By MedXY 11/02/2025

This case series evaluates relapse rates associated with various maintenance immunotherapies in 54 patients with Susac syndrome, highlighting treatment efficacy and challenges in managing this rare autoimmune disorder.